SAN FRANCISCO—The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies — just as it is in patients overall — according to a retrospective analysis reported to the ASCO Genitourinary Symposium by Professor Giuseppe Procopio, who is a clinical researcher specializing in medical therapies for genitourinary cancers at the Istituto Nazionale dei Tumori in Milan. In his presentation, however, he highlighted the need for randomized controlled studies to determine the effects of nephrectomy on the disease process. He explained that currently it is unclear whether surgery is causative of a good outlook or whether patients whose metastases emerged later have more benign disease than those whose disease becomes metastatic sooner.
Professor Giuseppe Procopio
Clinical specialist in medical therapies for genitourinary cancers
Department of Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract number: 517
Title: Time from nephrectomy (Nx) as an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapies (TTs).
Web link: http://meetinglibrary.asco.org/content/124068-142